Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Maastricht University Medical Center
Memgen, Inc.
Exelixis
Eli Lilly and Company
Astellas Pharma Inc
OHSU Knight Cancer Institute
Fate Therapeutics
Tempest Therapeutics
Fate Therapeutics
Bristol-Myers Squibb
Celgene